Actinium Pharma is a clinical-stage biopharmaceutical company developing targeted radiotherapies for oncology, combining radiochemistry expertise with deep tumor biology to create first-in-class radioconjugate therapeutics designed to treat solid tumors and hematologic malignancies. The company's pipeline includes lead programs in prostate cancer, lung cancer, and breast cancer, as well as late-stage hematology franchises addressing acute myeloid leukemia and bone marrow transplantation, targeting major cancer centers and quaternary care facilities. Actinium monetizes its platform through strategic partnerships with resource-rich pharmaceutical companies for late-stage program development, leveraging government collaborations to reduce costs while retaining commercial rights, and pursues out-licensing of its proprietary manufacturing capabilities and intellectual property portfolio.